SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories informs about media release

06 Aug 2024 Evaluate

Ipca Laboratories has informed that it enclosed the media release issued by the Company with respect to launch of patented novel drug branded as ‘Diulcus’ in the Indian market for treatment of Diabetic Foot Ulcer (DFU). Currently there is a global unmet medical need for treatment of DFU which is the most prevalent complication caused by chronic diabetes.

The above information is a part of company’s filings submitted to BSE.


Ipca Laboratories Share Price

1543.95 13.35 (0.87%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×